Memantine Augmentation in Obsessive-Compulsive Disorder

• Status: Completed
• Trial end date: 2008-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether memantine is safe and effective when used as an augmentation to standard treatment for Obsessive-Compulsive Disorder (OCD).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University
• Treatments: Memantine

Criteria

Inclusion Criteria:

• at least 18 years of age

• suffering from OCD

• Y-BOCS score of 18 or greater

• taking a therapeutic dose of an anti-OCD medication specified in the protocol

Exclusion Criteria:

• diagnosed with a mental disorder other than OCD

• taking tiagabine or pregabalin

• having had a previous trial of memantine

• receiving therapy for OCD

• substance abuse in the last 6 months

• personality disorders sufficiently severe to interfere with study participation